KR20170006971A - Composition for inhibiting urease activity of helicobater pylori and composition for preventing or treating damages of gastric mucosa - Google Patents
Composition for inhibiting urease activity of helicobater pylori and composition for preventing or treating damages of gastric mucosa Download PDFInfo
- Publication number
- KR20170006971A KR20170006971A KR1020150098478A KR20150098478A KR20170006971A KR 20170006971 A KR20170006971 A KR 20170006971A KR 1020150098478 A KR1020150098478 A KR 1020150098478A KR 20150098478 A KR20150098478 A KR 20150098478A KR 20170006971 A KR20170006971 A KR 20170006971A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- hot spring
- helicobacter pylori
- present
- spring water
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 108010046334 Urease Proteins 0.000 title claims abstract description 28
- 230000006378 damage Effects 0.000 title claims abstract description 16
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 11
- 230000000694 effects Effects 0.000 title abstract description 26
- 210000001156 gastric mucosa Anatomy 0.000 title abstract description 11
- 241000590002 Helicobacter pylori Species 0.000 claims abstract description 28
- 229940037467 helicobacter pylori Drugs 0.000 claims abstract description 26
- 235000013376 functional food Nutrition 0.000 claims abstract description 10
- 230000036541 health Effects 0.000 claims abstract description 9
- 230000002496 gastric effect Effects 0.000 claims description 17
- 229910004298 SiO 2 Inorganic materials 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 5
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 62
- 208000007882 Gastritis Diseases 0.000 abstract description 8
- 208000007107 Stomach Ulcer Diseases 0.000 abstract description 4
- 201000005917 gastric ulcer Diseases 0.000 abstract description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 3
- 235000020510 functional beverage Nutrition 0.000 abstract description 3
- 206010017758 gastric cancer Diseases 0.000 abstract description 3
- 210000002784 stomach Anatomy 0.000 abstract description 3
- 201000011549 stomach cancer Diseases 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 208000018556 stomach disease Diseases 0.000 abstract 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 18
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 15
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 15
- 239000012153 distilled water Substances 0.000 description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 9
- 229960000905 indomethacin Drugs 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 7
- 208000018522 Gastrointestinal disease Diseases 0.000 description 6
- 230000035622 drinking Effects 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 5
- 229940126409 proton pump inhibitor Drugs 0.000 description 5
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229960000381 omeprazole Drugs 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 101000808346 Canavalia ensiformis Urease Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000003673 groundwater Substances 0.000 description 2
- 159000000011 group IA salts Chemical class 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100476480 Mus musculus S100a8 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- -1 VacA Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
Abstract
Description
본 발명은 위 점막 손상의 예방 및 치료용 조성물, 헬리코박터 파이로리 균의 우레아제 활성 저해능을 지닌 조성물 및 이를 함유하는 건강기능식품에 관한 것이다.The present invention relates to a composition for the prevention and treatment of gastric mucosal injury, a composition having the ability to inhibit urease activity of Helicobacter pylori, and a health functional food containing the same.
온천수는 땅표면에서 자연용출 되거나 인공적으로 착정시추하여 끌어올린 지하수로 정의되는 것으로서, 수온이 그 지역의 연평균 기온 또는 그 지역의 얕은 지층의 지하수 수온보다 높아야 한다. 이에 비교하여 그 이하의 것은 냉천, 수온과 관계없이 무기물질 또는 가스성분을 다량 함유하고 있는 것은 광천이라고 한다.Hot springs are defined as groundwater that is spontaneously released from the surface of the earth or artificially drilled and raised. The water temperature should be higher than the average annual temperature of the area or the groundwater temperature in the shallow strata of the area. Compared to this, it is said that less than that is a mineral spring that contains a large amount of inorganic substance or gas component irrespective of cold weather and water temperature.
온천의 한계 온도는 지역에 따라 다르며, 우리나라는 섭씨 25℃ 이상을 온천으로 규정하고 있으며, 영국, 독일, 프랑스 등은 섭씨 20℃ 이상을, 미국은 21.1℃ 이상을 온천으로 규정하고 있다. The limit temperature of a hot spring varies according to the region. In Korea, the hot spring is prescribed as 25 ° C or more. In the United Kingdom, Germany, France, etc., the temperature is above 20 ° C.
또한, 우리나라는 온천을 지하로부터 용출되는 섭씨 25℃ 이상의 온수로 그 성분이 인체에 해롭지 아니한 것으로 규정하고 있으며[온천법(81.3.2.법률 3377호), 온천법시행령(81.6.18.대통령령10354호)], 온천학 상으로 좁은 뜻의 온천은 물리적, 화학적으로 보통의 물과는 성질이 다른 천연의 특수한 물이 땅속에서 지표로 나오는 현상이다.In Korea, hot water is hot water of 25 ℃ or more, which is extracted from underground, and it is prescribed that the constituents are not harmful to human body. [Hot Spring Act (81.3.2. Law 3377), Hot Spring Act Enforcement Decree (81.6.18. ], Hot spring The narrow sense of hot springs is a phenomenon in which natural, special water, which is physically and chemically different from ordinary water, comes out from the ground to the surface.
이와 같은 온천수의 물리적 작용에 의한 효과로는 일반적 혈액순환 항진효과, 진통 완화효과, 진정효과,및 피부미용효과 등이 있다.The effects of the physical action of the hot spring water include general circulation enhancement effect, pain relief effect, soothing effect, and skin beauty effect.
한편, 헬리코박터 파이로리(Helicobacter pylori)균은 1982년 호주의 Marshall과 Warren에 의하여 인체의 위점막에서 처음 분리된 이래, 만성위염 및 소화성 궤양의 주요 원인균임이 밝혀졌으며, 1994년에는 세계보건기구 산하 국제 암연구기관에서 발암인자의 하나로 규명되었다. 이 균은 몇 개의 편모를 가진 그람음성 간균으로 위 점막층의 표층이나 점액 내에 증식하며 가장 특징적인 미생물학적 성상으로서 강력한 운동성과 유레아제(urease)효소 활성을 가지고 있다.Since Helicobacter pylori was first isolated from the gastric mucosa of humans by Marshall and Warren in Australia in 1982, it has been identified as a major cause of chronic gastritis and peptic ulcer. In 1994, It was identified as one of the carcinogenic factors in the research institute. This bacterium is a gram-negative bacillus with several flagella, and it grows in the surface layer or mucus of the gastric mucosal layer. It has the most characteristic microbiological characteristics and has strong motility and urease enzyme activity.
헬리코박터 파이로리균은 강력한 요소 분해효소인 우레아제(urease)를 분비하여 위액내의 요소(H2NCONH2, urea) 1 분자를 가수분해하여 2분자의 암모니아(NH3)를 형성한다. 이 세균의 우레아제는 인체 위장관 표피세포에 헬리코박터 파이로리균을 감염시키고, 콜로니화(집락화, colonization)를 돕는 것에 대한 밀접한 관련성이 있다고 보고된다. 구체적으로, 우레아제를 불활성화시킨 헬리코박터 파이로리 균주는 위 점막세포에서 콜로니화하지 못하며, 우레아제 활성이 헬리코박터 파이로리의 콜로니화에 필수적이라는 보고가 있으며(Eaton K.A., et al., Infect Immun., 59, pp2470-2475, 1991), 헬리코박터 파이로리 우레아제에 의해 생성된 암모니아는 위액내 pH를 증가시키고, 위 점액층을 손상시키며(Sidebotham R.L., et al., J. Clin. Pathol., 44, pp52-57, 1991), 암모니아 자체가 위 점액층 세포의 산소소비와 미토콘드리아의 ATP 생성을저해하고(Tsujii M., et al., Gastroenterology, 102, pp1881-1888, 1992), 궁극적으로 암모니아는 모노클로로아민 (monochloroamine)을 형성하여 반응성 산소종(reactive oxygen species)을 생성하기 때문에 세포손상을 유발하여 만성염증을 일으키고, 나아가 DNA 손상을 일으켜 암발생 과정을 촉진시킨다는 보고가 있다(Hahm K.B., et al., Am. J. Gastroenterol., 92, pp1853-1857, 1997).Helicobacter pylori secretes urease, a powerful urease, and hydrolyzes one molecule of H 2 NCONH 2 , urea in gastric juice to form two molecules of ammonia (NH 3 ). The bacterium's urease has been reported to be closely related to Helicobacter pylori infection in human gastrointestinal epidermal cells and to help colonization (colonization). Specifically, it has been reported that the Helicobacter pylori strain inactivated with urease does not colonize gastric mucosal cells, and urease activity is essential for colonization of Helicobacter pylori (Eaton KA, et al., Infect Immun., 59, pp2470 -2475, 1991), ammonia produced by Helicobacter pylori urease increases pH in the gastric juice and damages the gastric mucosal layer (Sidebotham RL, et al., J. Clin. Pathol., 44, pp52-57, 1991) , Ammonia itself inhibits oxygen uptake in the gastric mucosal cells and ATP production in mitochondria (Tsujii M., et al., Gastroenterology, 102, pp1881-1888, 1992). Ultimately, ammonia forms monochloroamine (Reactive oxygen species), thereby causing cellular damage, causing chronic inflammation, and further damaging DNA, thereby promoting the development of cancer (Hah M. KB, et al., Am. J. Gastroenterol., 92, pp. 1853-1857, 1997).
상기와 같은 헬리코박터 파이로리 우레아제의 활성을 저해하기 위해 항생제 요법이 사용되고 있으나, 항생제 내성 균주의 출현으로 인해 효율성이 떨어지는 문제가 있다. 따라서, 최근에는 헬리코박터 파이로리를 제균할 수 있는 효과적인 방법으로 다양한 백신이 개발되고 있으며, 이들 중 대부분은 헬리코박터 파이로리의 병원성에 특이적인 표적인자(antigen)로 알려진 우레아제, VacA, CagA 및 뉴트로필-활성단백질(neutrophil-activating protein; NAP)과 같은 단백질을 표적으로 하는 억제자의 탐색에 대한 연구들이 진행되고 있다.Antibiotic therapy has been used to inhibit the activity of Helicobacter pylori urease as described above, but the efficiency is low due to the emergence of antibiotic resistant strains. Recently, a variety of vaccines have been developed as an effective method for eradicating Helicobacter pylori. Most of them are urease, VacA, CagA and Neutrophil-active protein known as antigens specific for the pathogenicity of Helicobacter pylori (NAP), which is known to be involved in the pathogenesis of cancer.
현재까지, 온천수의 음용은 위 점막의 혈류를 증가시키고 위액의 분비를 증가 혹은 억제하는 작용이 있다고 알려져 왔으나, 온천수의 음용이 사람의 위에서 기생하여 살면서 위염, 소화성 궤양, 위암의 원인으로 알려진 헬리코박터 파이로리균에 대한 항균효과를 지니거나 항우레아제 활성을 지닌다는 구체적인 보고는 아직 미흡한 실정이다.To date, the drinking of hot spring water has been known to increase the blood flow of the gastric mucosa and increase or inhibit the secretion of gastric juice. However, the drinking of hot spring water is parasitic on the human body and is caused by gastritis, peptic ulcer, Specific antimicrobial activity or anti-urease activity has not yet been reported.
본 발명은 상기와 같은 문제점을 해결하기 위해 안출된 것으로서, 본 발명자는 백암 및 덕구 지역의 온천수를 음용하도록 한 흰 쥐를 대상으로, 위 점막의 손상 정도 감소 및 위장 내 헬리코박터 파이로리 우레아제의 활성 억제를 확인하여, 이에 기초하여 본 발명을 완성하게 되었다.DISCLOSURE OF THE INVENTION The present invention was conceived to solve the above-mentioned problems. The present inventors have conducted a study on white rats that were allowed to consume hot spring water in Baekam and Deokgu area, and found that the decrease in the degree of damage of the gastric mucosa and the inhibition of the activity of H. pylori- And the present invention has been completed on the basis thereof.
이에, 본 발명의 목적은 백암 또는 덕구 지역 온천수와 동일 내지 유사한 성분을 포함하는 것을 특징으로 하는, 위 점막 손상의 예방 및 치료용 조성물을 제공하는 것이다.Accordingly, an object of the present invention is to provide a composition for preventing and treating gastric mucosal damage, which comprises the same or similar components as Baekam or Deokgu area hot spring water.
본 발명의 다른 목적은 백암 또는 덕구 지역의 온천수와 동일 내지 유사한 성분을 포함하는, 헬리코박터 파이로리의 우레아제 활성 저해능을 지닌 조성물을 제공하는 것이다.Another object of the present invention is to provide a composition having the ability to inhibit the urease activity of Helicobacter pylori, which comprises the same or similar components as the hot spring water of Baekam or Deokgu area.
본 발명의 또 다른 목적은 백암 또는 덕구 지역의 온천수와 동일 내지 유사한 성분을 함유하는, 건강기능식품을 제공하는 것이다.Another object of the present invention is to provide a health functional food containing the same or similar components as the hot spring water of Baekam or Deokgu area.
그러나 본 발명이 이루고자 하는 기술적 과제는 이상에서 언급한 과제에 제한되지 않으며, 언급되지 않은 또 다른 과제들은 아래의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.However, the technical problem to be solved by the present invention is not limited to the above-mentioned problems, and other matters not mentioned can be clearly understood by those skilled in the art from the following description.
상기와 같은 본 발명의 목적을 달성하기 위하여, 본 발명은 백암 또는 덕구 지역의 온천수와 동일 내지 유사한 성분을 포함하는, 위 점막 손상의 예방 및 치료용 조성물을 제공한다.In order to achieve the object of the present invention, the present invention provides a composition for prevention and treatment of gastric mucosal damage, which comprises the same or similar components as the hot spring water of Baekam or Deokgu area.
또한, 본 발명은 백암 또는 덕구 지역의 온천수와 동일 내지 유사한 성분을 포함하는, 위장 내 헬리코박터 파이로리의 우레아제 활성 저해능을 지닌 조성물을 제공한다.The present invention also provides a composition having the ability to inhibit the urease activity of gastric intestinal Helicobacter pylori, which comprises the same or similar components as the hot spring water of Baekam or Deokgu area.
또한, 본 발명은 백암 또는 덕구 지역의 온천수와 동일 내지 유사한 성분을 함유하는, 건강기능식품을 제공한다.In addition, the present invention provides a health functional food containing the same or similar components as the hot spring water of Baekam or Deokgu area.
본 발명의 일 구현예로서, 상기 조성물은 K 0.60 내지 0.80 mg/L, Na 41.00 내지 47.00 mg/L, Ca 1.9 내지 3.0 mg/L, Cl 4.40 내지 10.00 mg/L, SO45.20 내지 16.00mg/L, HCO389.70 내지 134.00mg/L, SiO2 34.00 내지 87.00mg/L, F 4.2 내지 10.30mg/L, Li 0.04 내지 0.08 mg/L, Sr 0.03 이하 mg/L, Zn 0.01 이하 mg/L및 Al 0.01 내지 0.016 mg/L의 성분을 함유하는 것이 바람직하다.In one embodiment of the present invention, the composition K 0.60 to 0.80 mg / L, Na 41.00 to 47.00 mg / L, Ca 1.9 to 3.0 mg / L, Cl 4.40 to 10.00 mg / L, SO 4 5.20 to 16.00mg / L, HCO 3 89.70 to 134.00 mg / L, SiO 2 Those containing components of 34.00 to 87.00 mg / L, F 4.2 to 10.30 mg / L, Li 0.04 to 0.08 mg / L, Sr 0.03 or less mg / L, Zn 0.01 or less mg / L and Al 0.01 to 0.016 mg / desirable.
본 발명에 따르는 조성물은 위 점막 손상 정도를 감소시키고, 위에서 기생하는 헬리코박터 파이로리의 우레아제 활성을 저해시켜, 헬리코박터 파이로리균에 의해 발생하는 위암, 위궤양, 위염 등 각종 위장관련 질병의 치료 및 예방용으로 활용이 가능하며, 위염과 같은 위장 질환의 개선에 효과적인 기능성 음료, 건강 기능 식품 등의 기능성 식품 분야에 유용하게 이용될 수 있다.The composition according to the present invention reduces the degree of gastric mucosal damage and inhibits the urease activity of parasitic Helicobacter pylori from above, and is used for the treatment and prevention of various gastrointestinal diseases such as gastric cancer, gastric ulcer and gastritis caused by Helicobacter pylori. And can be usefully used in functional foods such as functional beverages and health functional foods effective for the improvement of gastrointestinal diseases such as gastritis.
도 1은 흰 쥐의 온천수 음용시, NSAID(Indomethacin) 투여에 의한 위점막 손상 정도를 육안 수준으로 나타내어 비교한 것이다.
도 2는 흰 쥐의 온천수 음용시, NSAID(Indomethacin) 투여에 의한 위점막 손상 정도를 현미경 수준으로 나타내어 비교한 것이다.
도 3은 흰 쥐의 온천수 음용시, NSAID(Indomethacin) 투여에 의한 위점막 손상 정도를 비교한 결과를 그래프로 나타낸 것이다.
도 4는 온천수 및 증류수에서 증식한 헬리코박터 파이로리 균(26695) 및 배양액 상층부의 우레아제 활성 억제효과를 비교한 결과를 그래프로 나타낸 것이다.
도 5및 도 6은 in vitro 에서 Jack bean urease 활성도에 대한 덕구, 백암 온천수의 억제 효과를 나타낸 것이다.FIG. 1 is a graph comparing the degree of gastric mucosal injury by administration of NSAID (Indomethacin) at the visual level when drinking white water in hot water.
FIG. 2 is a graph comparing the degree of gastric mucosal damage by administration of NSAID (Indomethacin) at the microscopic level when drinking white water in hot water.
FIG. 3 is a graph showing the results of comparing the degree of gastric mucosal damage by administration of NSAID (Indomethacin) when drinking white water in a hot spring water.
Fig. 4 is a graph showing the results of comparing the effect of inhibiting urease activity of Helicobacter pylori (26695) grown in hot spring water and distilled water and the upper part of the culture liquid.
FIGS. 5 and 6 show the inhibitory effects of Jack and Bean spa waters on Jack bean urease activity in vitro.
이하,본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 백암 또는 덕구 지역 온천수와 동일 내지 유사한 성분을 포함하는 것을 특징으로 하는, 위 점막 손상의 예방 및 치료용 조성물을 제공한다. 또한, 본 발명은 백암 또는 덕구 지역 온천수와 동일 내지 유사한 성분을 포함하는 것을 특징으로 하는, 헬리코박터 파이로리 균의 우레아제 저해능을 지닌 조성물을 제공한다.The present invention provides a composition for preventing and treating gastric mucosal damage, which comprises the same or similar components as Baekam or Deokgu regional hot spring water. The present invention also provides a composition having the ability to inhibit urease activity of Helicobacter pylori, which comprises the same or similar components as Baekam or Deokgu regional hot spring water.
이 때, 상기 조성물은 K 0.60 내지 0.80 mg/L, Na 41.00 내지 47.00 mg/L, Ca 1.9 내지 3.0 mg/L, Cl 4.40 내지 10.00 mg/L, SO4 5.20 내지 16.00 mg/L, HCO3 89.70 내지 134.00mg/L, SiO2 34.00 내지 87.00 mg/L, F 4.2 내지 10.30 mg/L, Li 0.04 내지 0.08 mg/L, Sr 0.03 이하 mg/L, Zn 0.01 이하 mg/L 및 Al 0.01 내지 0.016 mg/L의 성분을 함유하는 것이 바람직하다.Wherein the composition comprises at least one of K 0.60-0.80 mg / L, Na 41.00-47.00 mg / L, Ca 1.9-3.0 mg / L, Cl 4.40-10.00 mg / L, SO 4 5.20-16.00 mg / L, HCO 3 89.70 to 134.00mg / L, SiO 2 34.00 to 87.00 mg / L, F 4.2 to 10.30 mg / L, Li 0.04 to 0.08 mg / L, less than Sr 0.03 mg / L, or less Zn 0.01 mg / L and 0.01 to 0.016 mg Al / L < / RTI >
본 발명에 따르는 조성물은 헬리코박터 파이로리균에 의해 발생하는 위암, 위궤양, 위염 등 각종 위장관련 질병의 치료 및 예방용으로 활용이 가능하며, 가축의 분뇨에서 우레아제 활성에 의해 발생하는 암모니아의 생성을 억제할 수 있다는 점에서 환경개선제로서도 응용할 수 있다.The composition according to the present invention can be used for the treatment and prevention of various gastrointestinal diseases caused by Helicobacter pylori such as gastric cancer, gastric ulcer, gastritis and the like, and inhibits the production of ammonia caused by urease activity in the animal manure It can be applied as an environment improving agent.
또한, 본 발명은 백암 또는 덕구 지역 온천수와 동일 내지 유사한 성분을 포함하는 조성물을 함유하는 건강기능식품을 제공한다. 즉, 본 발명의 조성물은 위장 질환 개선을 위한 목적으로 식품 또는 음료에 첨가될 수 있다. 이때, 식품 또는 음료 중에 본 발명의 상기 온천수를 포함하는 조성물의 양은 일반적으로 전체 식품 중량의 10 내지 90 중량%로 가할 수 있으며, 위장 질환의 개선을 목적으로 한 기능성 음료, 환제, 정제 또는 상기 성분을 건조 분말화하여 충진한 연질 또는 경질 캡슐제의 형태로 이용할 수 있고, 음료 조성물에는 100 ㎖를 기준으로 10 내지 90 ㎖의 비율로 본 발명의 조성물을 가할 수 있다.The present invention also provides a health functional food containing a composition comprising the same or similar components as Baekam or Deokgu area spring water. That is, the composition of the present invention can be added to food or beverage for the purpose of improving gastrointestinal diseases. At this time, the amount of the composition including the hot spring water of the present invention in the food or beverage may be generally 10 to 90% by weight of the total food weight, and may be a functional beverage, a pill, a tablet, May be used in the form of a soft or hard capsule filled with a dry powder. The composition of the present invention may be added to the beverage composition at a ratio of 10 to 90 ml based on 100 ml.
본 발명의 건강 음료 조성물은 필수 성분으로서 상기 조성물을 함유하는 외에는 액체성분에는 특별한 제한점은 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등의 디사카라이드, 예를 들어 말토스, 슈크로스 등의 폴리사카라이드, 예를들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로약 1 내지 20g, 바람직하게는 약 5 내지 12g이다.The health beverage composition of the present invention is not particularly limited to a liquid ingredient other than the above-mentioned composition as an essential ingredient, and may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose, polysaccharides such as maltose, sucrose and the like, such as dextrin, cyclodextrin and the like And sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 조성물은 여러가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 조성물들은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다.In addition to the above-mentioned composition, the composition of the present invention can be used as a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and aging agents (cheese, chocolate etc.), pectic acid and its salts, , Organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. In addition, the compositions of the present invention may contain flesh for the production of natural fruit juices and fruit juice drinks and vegetable drinks. These components may be used independently or in combination.
본 명세서에서 사용된 것으로, NSAID 제제는 비스테로이드성 항염증제로서 다양한 질환을 치료하기 위해 전세계적으로 널리 사용되고 있는 물질이다. 그러나 이들은 산성의 성질을 띠므로 점막을 직접적으로 손상시키고, 점막의 프로스타글란딘의 합성을 저해하는 등 위장질환을 일으키는 것으로 널리 알려져 있다.As used herein, NSAID formulations are non-steroidal anti-inflammatory agents and have been widely used worldwide for the treatment of various diseases. However, they are known to cause gastrointestinal diseases such as damaging the mucous membrane directly and inhibiting the synthesis of prostaglandins in the mucous membrane due to their acidic nature.
본 명세서에서 사용된 것으로, PPI는 프로톤 펌프 억제제의 약어이며, 따라서 에소메프라졸, 또는 그의 알칼리성 염 또는 이들 중의 어느 하나의 수화된 형태뿐만 아니라 오메프라졸, 또는 그의 알칼리성 염 또는 이 들 중의 어느 하나의 수화된 형태를 포함한다. 상기 프로톤 펌프 억제제는 위산의 분비를 억제해주는 제제로서, 위염, 위궤양, 십이지장 궤양과 같은 위장질환의 증상을 감소시키는 효과를 띤다.As used herein, PPI is an abbreviation for a proton pump inhibitor and is therefore intended to include omeprazole, or an alkaline salt thereof, or a hydrated form of any of them, as well as omeprazole, or an alkaline salt thereof, Including hydrated forms. The proton pump inhibitor is an agent for suppressing the secretion of gastric acid and has an effect of reducing symptoms of gastrointestinal diseases such as gastritis, gastric ulcer, duodenal ulcer.
이하, 본 발명의 구성을 하기의 실시예를 통하여 상세히 설명하기로 한다. 다만, 본 발명의 권리범위는 하기 실시예에 의하여 특허청구범위가 제한되는 것은 아니다.Hereinafter, the structure of the present invention will be described in detail with reference to the following examples. However, the scope of the present invention is not limited by the following embodiments.
실시예 1. 백암 및 덕구 온천수의 주요 원소 함유량 검출Example 1. Detecting the content of major elements in Baekam and Deokgu hot spring water
백암 및 덕구 온천수의 주요 원소 함유량은 한국온천의 현황과 이용(이종태, ㈜한국중앙온천연구소, 2008년 12월 발행)에서 발췌하였다.The contents of major elements of Baekam and Deokgu hot spring water were extracted from the present situation and utilization of Korean hot springs (Lee, Jong Tae, Korea Central Hot Spring Research Institute, December 2008 issue).
실시예 2. 위점막의 손상 정도 감소의 측정Example 2. Measurement of the degree of damage of gastric mucosa
실험동물로는 체중이 158g~160g (6주령, M) 되는 Sprague Dawley (SD) rat (오리엔트바이오 사) 37마리를 이용하였다. As experimental animals, 37 Sprague Dawley (SD) rats weighing 158g ~ 160g (6 weeks old, M) were used.
상기 37마리의 흰 쥐는수도물 처리군 3마리, 덕구온천수 처리군 4마리, 백암온천수 처리군 4마리, NSAID (Indomethacin,80mg/kg)처리군 6마리, NSAID(Indomethacin, 180mg/kg) 및 덕구온천수 처리군 6마리, NSAID (Indomethacin , 180mg/kg)및 백암온천수 처리군 6마리, NSAID 및 PPI(omeprazole, 30mg/kg + Indomethacin, 180mg/kg)처리군 6마리로 나누었다.The 37 rats were divided into three groups: three in the tap water treatment group, four in the Deokgu hot spring water treatment group, four in the Baekam spring water treatment group, six in the NSAID treatment group (Indomethacin, 80 mg / kg), the NSAID (Indomethacin, 180 mg / kg) Six treatment groups, 6 NSAIDs (Indomethacin, 180 mg / kg) and Baekam spring water treatment group, and 6 NSAID and PPI treatment groups (omeprazole, 30 mg / kg + Indomethacin, 180 mg / kg)
온천수 및 NSAID를 처리한 군은, 먼저 5 내지 6일 정도 온천수를 음용 시킨 후에 NSAID를 투여 하였다. NSAID처리는 Indomethacin을 Tris(PH 8.0)에 녹이고 180mg/kg 의 양으로 1번 투여하였다. PPI처리는 Omeprazole을 생리식염수에 녹이고 30mg/kg 의 양으로 피하주사 처리하였고, Indomethacin을 180mg/kg 의 양으로 복강 내 1번 투여하였다.In the group treated with hot spring water and NSAID, NSAID was administered after drinking hot spring water for 5 to 6 days. NSAID treatment was performed by dissolving indomethacin in Tris (pH 8.0) and once at a dose of 180 mg / kg. In PPI treatment, omeprazole was dissolved in physiological saline, subcutaneously injected at a dose of 30 mg / kg, and indomethacin was administered once intraperitoneally at a dose of 180 mg / kg.
이후, 24시간이 경과한 다음날 흰 쥐를 희생시켜 샘플을 얻었으며, 위 조직을 4% PFA 에 고정시틴 다음 파라핀에 포매시키고 paraffin block을 만들어 5 μm 두께로 절단하고, H&E stain을 한 후 육안 및 광학 현미경으로 관찰한 결과를 각각 도 1 및 도 2에 나타내었다.After 24 hours, the rat was sacrificed and the stomach tissue was immobilized on 4% PFA, then embedded in paraffin, paraffin block was cut into 5 μm thick, and H & E stain was performed. And observation with an optical microscope are shown in Figs. 1 and 2, respectively.
도 1의 NSAID만을 처리한 군에서는 검은색의 위점막 점상출혈을 나타내고, 도 2의 NSAID만을 처리한 군에서는 상대적으로 흰 색의 위점막 손상부분을 나타내고 있어, 위 점막이 손상된 것을 알 수 있었다. 그러나, NSAID 및 온천수를 처리한 군에서는 상기 점상출혈 및 흰 색의 위점막 손상부분이 나타나지 않아, 위 점막이 손상되지 않음을 알 수 있었다.In the group treated with only the NSAID of FIG. 1, the gastric mucosal papillary hemorrhage was shown to be black. In the group treated with only the NSAID shown in FIG. 2, the gastric mucosa was damaged due to the relatively white color. However, in the group treated with NSAID and hot water, it was found that the gastric mucosa was not damaged because the petechiae bleeding and white staining of the gastric mucosa were not observed.
이를 통하여, 백암 또는 덕구 온천수와 동일 내지 유사한 성분을 포함하는 조성물은 위 점막의 손상을 예방하거나 치료할 수 있음을 확인하였다.Through this, it was confirmed that a composition comprising the same or similar components as Baekam or Deokgu hot spring water can prevent or treat gastric mucosal damage.
실시예 3. 헬리코박터 파이로리 균의 우레아제 저해활성의 측정Example 3: Measurement of urease inhibitory activity of Helicobacter pylori
먼저 증류수와 온천수를 465ml각각에 브레인-하트 인퓨전(BD) 18.5g을 충분히 녹인 후에, 오토클레이빙을 하였다. 이 후, 7% serum 35ml을 섞어서 배지를 만들고, 이에 헬리코박터 파이로리 균을 접종하여 37 °C, CO2 인큐베이터에서 배양하였다. First, 18.5 g of Brain-Heart Infusion (BD) was sufficiently dissolved in 465 ml of distilled water and hot spring water, respectively, followed by autoclaving. Subsequently, 35 ml of 7% serum was mixed to prepare a culture medium. Then, Helicobacter pylori was inoculated and cultured in a CO 2 incubator at 37 ° C.
이후,5일간 배양시킨 3가지 배지에서 헬리코박터 파이로리 균의 각 샘플을 채취하여,1.5내지 2ml의 쏘이 아가(soy agar)에 20% 우레아제 용액과 1:1로 접종시켰고, 맥팔랜드 수치를 0.08 내지 0.12의 범위 안에서 0.1로 맞춰주었다. 30분마다 헬리코박터 파이로리 균의 집락수를 측정하여 표 2에 나타내었다. 그 후증류수(DW), 덕구온천수,및 백암온천수를 30일 동안 먹인 후 증류수를 먹인 쥐와 온천수를 먹인 쥐에서 위 점막을 채취하여 혐기조건에서 세균배양을 하였다.Each sample of Helicobacter pylori was then harvested from three different mediums cultured for 5 days, 1.5-2 ml of soy agar was inoculated with a 20% urease solution at a ratio of 1: 1, and a McFarland value of 0.08-0.12 I set it to 0.1 in range. The number of colonies of Helicobacter pylori was measured every 30 minutes and is shown in Table 2. After the feeding of distilled water (DW), Deokgu hot spring water, and Baekam hot spring water for 30 days, the gastric mucosa was collected from rats fed with distilled water and hot spring water and cultured in anaerobic condition.
표 2에서 나타낸 것과 같이, 증류수에 비해 덕구 및 백암온천수를 음용한 생쥐에서 헬리코박터 파이로리 균의 우레아제 활성을 저해시켜, 헬리코박터 파이로리 균의 콜로니화를 억제함을 확인하였다. 도 4 에서와 같이 덕구 및 백암온천수에서 배양한 세균 및 배양 상층액의 우레아제 활성 역시 증류수에서 배양한 것에 비하여 그 활성도가 감소하였음을 알 수 있었다.As shown in Table 2, it was confirmed that inhibition of urease activity of Helicobacter pylori was inhibited in mice in which Deokgu and Baekam hot spring water were consumed compared with distilled water, thereby inhibiting colonization of Helicobacter pylori. As shown in FIG. 4, the urease activity of the bacteria and culture supernatant cultured in Deokgu and Baekam hot spring water was also decreased compared with that in the distilled water.
이를 통하여, 백암 또는 덕구온천수와 동일 내지 유사한 성분을 포함하는 조성물은 헬리코박터 파이로리 균의 우레아제 활성을 저해시켜, 헬리코박터 파이로리 균의 콜로니화를 억제함을 확인하였다.Through this, it was confirmed that the composition comprising the same or similar components as Baekam or Deokgu hot spring water inhibited the urease activity of Helicobacter pylori bacteria and inhibited the colonization of Helicobacter pylori bacteria.
실시예 4. 잭 빈 우레아제 저해활성의 측정Example 4. Measurement of jackin urease inhibitory activity
증류수(DW), 덕구온천수, 및 백암온천수 각각의 우레아제 저해 활성을 다음과 같은 방법으로 측정하였고 그 결과를 도 5 및 도 6에 나타내었다.The urease inhibitory activity of each of the distilled water (DW), Deokgu hot spring water, and Baekam hot spring water was measured by the following method, and the results are shown in FIG. 5 and FIG.
잭 빈 우레아제(Jack bean urease : Sigma type III, Sigma Co.) 효소 용액(5㎕) 0.1㎖를 3mM 포스페이트완충용액(phosphate buffer solution : pH 6.8) 2.5㎖, 페놀 레드(phenol red) 0.1㎖(7㎍/㎖) 및 0.4㎖ 우레아(10, 20% urea 용액)를 포함한 1cm 길이의 큐베트(cuvette)에 넣고 23에서 분광광도계(SpectronicGenesys, Spectronic Inc., USA)로 OD560의 경시변화를 조사하여 30분마다 측정하였다. 속도는 곡선의 직선 부분(0.15 ~0.5 OD unit)의 기울기로부터 계산되었다.0.1 ml of a jack bean urease (Sigma type III, Sigma Co.) enzyme solution (5 μl) was added to 2.5 ml of a 3 mM phosphate buffer solution (pH 6.8), 0.1 ml of phenol red (SpectronicGenesys, Spectronic Inc., USA) was used to examine the change of OD560 over time to determine the time course of OD560. Min. The velocity was calculated from the slope of the straight line portion of the curve (0.15-0.5 OD unit).
도 5및 도 6에 나타낸 것과 같이, 덕구 및 백암온천수 각각은 잭 빈 우레아제 저해 활성을 나타냄을 알 수 있었다.As shown in FIG. 5 and FIG. 6, it was found that each of Deokgu and Baekam hot spring water exhibited Jackin urease inhibitory activity.
Claims (3)
K 0.60-0.80 mg / L, Na 41.00-400.00 mg / L, Ca 1.9-3.0 mg / L, Cl 4.40-10.00 mg / L, SO 4 5.20-16.00 mg / L, HCO 3 89.70-134.00 mg / Containing components of 34.00 to 87.00 mg / L of SiO 2 , 4.2 to 10.30 mg / L of Li, 0.04 to 0.08 mg / L of Li, 0.03 mg / L of Sr or less, 0.01 or less mg / L of Zn and 0.01 to 0.016 mg / Health functional foods.
K 0.60-0.80 mg / L, Na 41.00-400.00 mg / L, Ca 1.9-3.0 mg / L, Cl 4.40-10.00 mg / L, SO 4 5.20-16.00 mg / L, HCO 3 89.70-134.00 mg / Containing components of 34.00 to 87.00 mg / L of SiO 2 , 4.2 to 10.30 mg / L of Li, 0.04 to 0.08 mg / L of Li, 0.03 mg / L of Sr or less, 0.01 or less mg / L of Zn and 0.01 to 0.016 mg / Or a pharmaceutically acceptable salt thereof, for the prevention and treatment of gastric mucosal injury.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150098478A KR101714448B1 (en) | 2015-07-10 | 2015-07-10 | Composition for inhibiting urease activity of helicobater pylori and composition for preventing or treating damages of gastric mucosa |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150098478A KR101714448B1 (en) | 2015-07-10 | 2015-07-10 | Composition for inhibiting urease activity of helicobater pylori and composition for preventing or treating damages of gastric mucosa |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170006971A true KR20170006971A (en) | 2017-01-18 |
KR101714448B1 KR101714448B1 (en) | 2017-03-09 |
Family
ID=57992678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150098478A KR101714448B1 (en) | 2015-07-10 | 2015-07-10 | Composition for inhibiting urease activity of helicobater pylori and composition for preventing or treating damages of gastric mucosa |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101714448B1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101071502B1 (en) * | 2008-06-18 | 2011-10-10 | 한국콜마 주식회사 | Fast dissoluble effervescent tablet containing mastic |
JP5014018B2 (en) * | 2006-10-18 | 2012-08-29 | 旭化成ケミカルズ株式会社 | Helicobacter pylori suppressor or bacteriostatic agent |
JP2013512960A (en) * | 2009-12-07 | 2013-04-18 | アイロンウッド ファーマシューティカルズ, インコーポレイテッド | Gastrointestinal disorder therapy |
KR101313597B1 (en) * | 2013-05-08 | 2013-10-01 | 김규한 | Fuctional beverage with immunopotentiation, improving constitution and fatigue recovery |
-
2015
- 2015-07-10 KR KR1020150098478A patent/KR101714448B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5014018B2 (en) * | 2006-10-18 | 2012-08-29 | 旭化成ケミカルズ株式会社 | Helicobacter pylori suppressor or bacteriostatic agent |
KR101071502B1 (en) * | 2008-06-18 | 2011-10-10 | 한국콜마 주식회사 | Fast dissoluble effervescent tablet containing mastic |
JP2013512960A (en) * | 2009-12-07 | 2013-04-18 | アイロンウッド ファーマシューティカルズ, インコーポレイテッド | Gastrointestinal disorder therapy |
KR101313597B1 (en) * | 2013-05-08 | 2013-10-01 | 김규한 | Fuctional beverage with immunopotentiation, improving constitution and fatigue recovery |
Also Published As
Publication number | Publication date |
---|---|
KR101714448B1 (en) | 2017-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chatterjee et al. | The bactericidal effects of Lactobacillus acidophilus, garcinol and Protykin® compared to clarithromycin, on Helicobacter pylori | |
KR100673605B1 (en) | The extract of Green Tea having inhibition activity for urease of Helicobacter pylori and the health functional food using thereof | |
KR101831932B1 (en) | Prophylactic or therapeutic kimchi for Helicobacter pylori-induced disease | |
KR20150093444A (en) | Composition with the extract of Cudrania tricuspidata for the prevention of gastritis and gastric ulcer | |
KR101714448B1 (en) | Composition for inhibiting urease activity of helicobater pylori and composition for preventing or treating damages of gastric mucosa | |
KR100526992B1 (en) | Fermented extract of a fruit of the trifoliate orange, and a composition for treating the disease caused by infection of helicobacter pylori | |
BOUHENNI | Study of combined effect of some medicinal plants and probiotics against Helicobacter pylori responsible for gastroduodenal diseases | |
Manyi-Loh et al. | Treatment of Helicobacter pylori infections: mitigating factors and prospective natural remedies | |
KR20110117540A (en) | A pharmaceutical composition for prevention or treatment of diseases related to helicobacter infection comprising extracts of sanguisorba officinalis as an effective component and a health food | |
KR102530415B1 (en) | Composition for preventing and treating gastrointestinal diseases, effective for killing Helicobacter pylori | |
KR101182053B1 (en) | An Antibacterial composition comprising the essential oil extract of Undaria pinnatifida Garney Suringar | |
CN103153304A (en) | Compositions for treating helicobacter pylori infection | |
KR101645721B1 (en) | Composition comprising mastic for preventing and treating gastric diseases | |
KR101644607B1 (en) | Compositions for Preventing or Treating for Diseases Derived from Helicobacter pylori comprising Extract of Black Rice and Health Food thereof | |
Shetty et al. | Antimicrobial activity of Anisochilus carnosus (LF) Wall against the Human gastric pathogen Helicobacter pylori | |
US20200254033A1 (en) | Composition for preventing and improving gastrointestinal disorder containing lactobacillus plantarum | |
KR101248741B1 (en) | An Antibacterial composition comprising the essential oil extract of Porphyra tenera | |
KR101750854B1 (en) | A antibiotic composition for Helicobacter pylori containing the propolis extraction fractions thereof or subfractional extrats isolated therefrom | |
KR20120113186A (en) | Composition comprising oriental herbal extract for preventing or treating gastrointestinal disorder | |
KR101700606B1 (en) | A antibiotic composition for Helicobacter pylori containing the purified bee venom | |
WO2005011671A1 (en) | Use of flavonoids for preventing and treating gastritis and gastric ulcer | |
KR100616914B1 (en) | Composition for treating or preventing gastritis and peptic ulcer comprising Rhizopus sp. | |
KR20180063597A (en) | Composition for inhibiting a growth of Helicobacter Pylori | |
US20060194746A1 (en) | Method and composition to inhibit infections with Helicobacter pylori by intake of procyanidins from type B and C | |
KR20030067200A (en) | Composition comprising flavonoids for preventing and treating gastritis and gastric ulcer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20200225 Year of fee payment: 4 |